Furosemide + Amiloride

This product is a fixed combination of two diuretics that act at different points along the kidney tubule and are given together to balance each other's effects ^[1][2]. Furosemide is a loop diuretic, one of the most potent classes of water tablet, which acts on the loop of Henle to flush out large amounts of salt and water; a known consequence of that action is the loss of potassium in the urine ^[2]. Amiloride is a potassium-sparing diuretic, a much weaker agent on its own, whose main value in the pairing is that it reduces the excretion of potassium and so helps guard against the low potassium levels that loop diuretics tend to cause ^[1]. The combination is known generically as co-amilofruse and is marketed under brand names including Frumil ^[1].

Each ingredient has a long independent history ^[1][2]. Furosemide was introduced in the 1960s and remains among the most widely used diuretics, familiar under the brand name Lasix ^[2]. Amiloride was approved in the United States in the early 1980s and is sold on its own as Midamor ^[1]. Both drugs feature on the World Health Organization's List of Essential Medicines, and pairing a loop or thiazide diuretic with amiloride to offset potassium loss is a long-established prescribing approach ^[1]. Combining them in a single tablet is intended to simplify treatment for people who need the fluid-clearing power of a loop diuretic but are at risk of becoming depleted of potassium ^[1].

The combination is used chiefly to treat oedema, the build-up of excess fluid in the body seen in heart failure and other conditions, where a strong diuretic effect is wanted without the accompanying fall in potassium ^[1][2]. By retaining potassium, amiloride can reduce the need for the separate potassium supplements that might otherwise accompany loop diuretic therapy ^[1]. As with furosemide used alone, the response to the loop component can be somewhat unpredictable because its absorption from the gut is variable and often incomplete ^[3]. The preparation is taken by mouth as a tablet ^[1].

The main hazard peculiar to this combination is the reverse of the problem the loop diuretic causes on its own; because amiloride conserves potassium, blood potassium can climb too high, a state called hyperkalaemia, which is especially a concern in people with impaired kidney function, diabetes, or advanced age ^[1]. For this reason blood chemistry is monitored, and the combination is used cautiously alongside other drugs that raise potassium ^[1]. The remaining side effects are largely those of the two ingredients individually, including dehydration and low blood pressure from excessive fluid loss, disturbances of other electrolytes such as sodium, and, from the loop component at high exposure, effects on hearing ^[2][4]. It is supplied only as an oral tablet in fixed ratios of the two drugs ^[1].

This is a prescription combination. Common effects include frequent urination, thirst, dizziness and low blood pressure. Electrolytes can shift in either direction, since furosemide lowers potassium, sodium and magnesium while amiloride raises potassium, so periodic blood tests are important. It can raise uric acid and trigger gout, and high doses of furosemide carry a small risk of hearing effects. It should be avoided in people with high potassium, severe kidney impairment or no urine output. Caution is needed with ACE inhibitors, ARBs or potassium supplements (added hyperkalemia risk from amiloride), with NSAIDs (which blunt the diuretic and stress the kidneys), and with lithium (reduced clearance).

This combination pairs two diuretics that were each developed independently during the mid-twentieth century golden age of renal pharmacology. Furosemide was synthesized by the German company Hoechst, patented in 1959 and introduced into clinical practice in the mid-1960s, quickly becoming the archetypal loop diuretic for its potent ability to clear excess fluid. Amiloride was developed by researchers at Merck in the 1960s as a potassium-sparing agent that blocks the epithelial sodium channel in the distal nephron.

The pharmacological logic of combining them is that the loop diuretic's strong fluid-clearing action tends to waste potassium, while the potassium-sparing agent offsets that loss, so the two together achieve diuresis with a steadier potassium balance. The fixed-dose preparation is known generically as co-amilofruse and has long been sold in the United Kingdom and elsewhere under brand names such as Frumil. Both furosemide and amiloride appear individually on the World Health Organization's List of Essential Medicines, a mark of their enduring clinical importance.

This pairing is a well-established, practical solution to a long-standing clinical problem: how to give the powerful fluid-clearing benefit of a loop diuretic without the troublesome drop in blood potassium it can cause. Clinicians value it for treating fluid retention in conditions such as heart failure, where keeping potassium stable matters for heart rhythm and patient safety. Both components are time-tested, inexpensive, and individually recognized as essential medicines by the World Health Organization, which speaks to the depth of experience behind them.

The fixed-dose format simplifies treatment by combining the two actions in a single tablet. As with any diuretic regimen, it requires monitoring of kidney function and electrolytes, and it is a symptomatic treatment for fluid overload rather than a cure for the underlying condition. Its longevity in everyday practice is a strong testament to how sensibly the two drugs complement each other.